Search Results
New horizons in high-risk HR+ HER2- EBC: Risk stratification for early identification
Identifying research priorities in risk stratification of patients with early breast cancer (Fab...
ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer
Continuous Abemaciclib Treatment Leads to Breast Cancer Inhibition | Oncotarget
New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer
Session 9: Adjuvant endocrine therapy for premenopausal women: Risk stratification, type & duration
Controversies in the treatment of the axilla
Optimizing Therapy in HER2+ Disease with Dr. Kevin Kalinsky
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients
Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast Cancer
ClarifyingComplexities of ExpandingTreatmentOptionsFor AdvancedAndEarly-Stage HR+/HER2- BreastCancer
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis
